RPRX Royalty Pharma plc

Price (delayed)

$43.96

Market cap

$17.06B

P/E Ratio

33.3

Dividend/share

$0.47

EPS

$1.32

Enterprise value

$21.87B

Sector: Healthcare
Industry: Biotechnology

Highlights

Royalty Pharma's gross profit has increased by 17% YoY and by 6% from the previous quarter
The revenue has increased by 17% YoY and by 6% from the previous quarter
RPRX's equity is down by 21% year-on-year but it is up by 8% since the previous quarter
The net income has plunged by 58% YoY and by 56% from the previous quarter
The company's quick ratio fell by 17% QoQ

Key stats

What are the main financial stats of RPRX
Market
Shares outstanding
388.13M
Market cap
$17.06B
Enterprise value
$21.87B
Valuations
Price to earnings (P/E)
33.3
Price to book (P/B)
3.54
Price to sales (P/S)
7.78
EV/EBIT
19.32
EV/EBITDA
19.32
EV/Sales
10.3
Earnings
Revenue
$2.12B
EBIT
$1.13B
EBITDA
$1.13B
Free cash flow
$2.03B
Per share
EPS
$1.32
Free cash flow per share
$5.42
Book value per share
$12.42
Revenue per share
$5.65
TBVPS
$42.59
Balance sheet
Total assets
$16.02B
Total liabilities
$6.12B
Debt
$5.82B
Equity
$4.82B
Working capital
$2.39B
Liquidity
Debt to equity
1.21
Current ratio
8.76
Quick ratio
6.82
Net debt/EBITDA
4.25
Margins
EBITDA margin
53.3%
Gross margin
100%
Net margin
45.9%
Operating margin
75.2%
Efficiency
Return on assets
6.4%
Return on equity
21%
Return on invested capital
5.9%
Return on capital employed
7.2%
Return on sales
53.3%
Dividend
Dividend yield
1.09%
DPS
$0.47
Payout ratio
35.5%

RPRX stock price

How has the Royalty Pharma stock price performed over time
Intraday
1.74%
1 week
4.99%
1 month
0.34%
1 year
N/A
YTD
-12.17%
QTD
0.78%

Financial performance

How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.12B
Gross profit
$2.12B
Operating income
$1.6B
Net income
$975.04M
Gross margin
100%
Net margin
45.9%
Royalty Pharma's net margin has shrunk by 65% YoY and by 59% QoQ
The net income has plunged by 58% YoY and by 56% from the previous quarter
The operating margin has declined by 48% year-on-year and by 42% since the previous quarter
The operating income has contracted by 39% YoY and by 39% from the previous quarter

Growth

What is Royalty Pharma's growth rate over time

Valuation

What is Royalty Pharma stock price valuation
P/E
33.3
P/B
3.54
P/S
7.78
EV/EBIT
19.32
EV/EBITDA
19.32
EV/Sales
10.3
RPRX's equity is down by 21% year-on-year but it is up by 8% since the previous quarter
The revenue has increased by 17% YoY and by 6% from the previous quarter

Efficiency

How efficient is Royalty Pharma business performance
The ROA has plunged by 68% YoY and by 59% from the previous quarter
Royalty Pharma's return on sales has shrunk by 63% YoY and by 56% QoQ
The ROIC has shrunk by 62% YoY and by 54% QoQ
RPRX's ROE has plunged by 53% from the previous quarter and by 53% YoY

Dividends

What is RPRX's dividend
DPS
$0.47
Dividend yield
1.09%
Payout ratio
35.5%

Financial health

How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 162% more than its total liabilities
Royalty Pharma's total assets has increased by 29% YoY
The company's quick ratio fell by 17% QoQ
Royalty Pharma's debt is 21% higher than its equity
RPRX's equity is down by 21% year-on-year but it is up by 8% since the previous quarter
The debt to equity has increased by 19% YoY but it has decreased by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.